Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 1/2019

Open Access 01-01-2019 | Review

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?

Authors: Hans Carl Hasselbalch, Morten Orebo Holmström

Published in: Seminars in Immunopathology | Issue 1/2019

Login to get access

Abstract

The first clinical trials of the safety and efficacy of interferon-alpha2 (IFN-alpha2) were performed about 30 years ago. Since then, several single-arm studies have convincingly demonstrated that IFN-alpha2 is a highly potent anti-cancer agent in several cancer types but unfortunately not being explored sufficiently due to a high toxicity profile when using non-pegylated IFN-alpha2 or high dosages or due to competitive drugs, that for clinicians at first glance might look more attractive. Within the hematological malignancies, IFN-alpha2 has only recently been revived in patients with the Philadelphia-negative myeloproliferative neoplasms—essential thrombocytosis, polycythemia vera, and myelofibrosis (MPNs)—and in patients with chronic myelogenous leukemia (CML) in combination with tyrosine kinase inhibitors. In this review, we tell the IFN story in MPNs from the very beginning in the 1980s up to 2018 and describe the perspectives for IFN-alpha2 treatment of MPNs in the future. The mechanisms of actions are discussed and the impact of chronic inflammation as the driving force for clonal expansion and disease progression in MPNs is discussed in the context of combination therapies with potent anti-inflammatory agents, such as the JAK1–2 inhibitors (licensed only ruxolitinib) and statins as well. Interferon-alpha2 being the cornerstone treatment in MPNs and having the potential of inducing minimal residual disease (MRD) with normalization of the bone marrow and low-JAK2V617F allele burden, we believe that combination therapy with ruxolitinib may be even more efficacious and hopefully revert disease progression in many more patients to enter the path towards MRD. In patients with advanced and transforming disease towards leukemic transformation or having transformed to acute myeloid leukemia, “triple therapy” is proposed as a novel treatment modality to be tested in clinical trials combining IFN-alpha2, DNA-hypomethylator, and ruxolitinib. The rationale for this “triple therapy” is given, including the fact that even in AML, IFN-alpha2 as monotherapy may revert disease progression. We envisage a new and bright future with many more patients with MPNs obtaining MRD on the above therapies. From this stage—and even before—vaccination strategies may open a new horizon with cure being the goal for some patients.
Literature
1.
Isaacs A, Lindenmann J, Virus interference I (1957) The interferon. Proc R Soc Lond B Biol Sci 147:258–267CrossRefPubMed
2.
Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8–32CrossRefPubMed
3.
Krause CD, Pestka S (2005) Evolution of the class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 106:299–346CrossRefPubMed
4.
Platanias LC (2005) Mechanisms of type-I- and type-II-interferon mediated signalling. Nat Rev Immunol 5:375–386CrossRefPubMed
5.
de Weerd NA, Samarajiwa SA, Hertzog PJ (2007) Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053–20057
6.
Pestka S (2007) The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282:20047–20051CrossRefPubMed
7.
Tough DF, Sun S, Zhang X, Sprent J (1999) Stimulation of naive and memory T cells by cytokines. Immunol Rev 170:39–47CrossRefPubMed
8.
Ortaldo JR, Mason A, Rehberg E et al (1983) Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J Biol Chem 258:15011–15015PubMed
9.
Cantell K, Hirvonen S, Kauppinen HL, Myllyla G (1981) Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 78(Part A):29–38CrossRefPubMed
10.
Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H (1979) Interferon therapy in myelomatosis. Lancet 313:245–247CrossRef
11.
Kujawski LA, Talpaz M (2007) The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 18(5–6):459–471CrossRefPubMed
12.
Guilhot F, Roy L, Saulnier PJ et al (2008) Immunotherapy of chronic myelogenous leukemia. Leuk Lymphoma 49(4):629–634CrossRefPubMed
13.
Essers MAG, Offner S, Blanco-Bose WE et al (2009) IFNa activates dormant haematopoietic stem cells in vivo. Nature 458:904–908CrossRefPubMed
14.
Trumpp A, Essers M, Wilson A (2010) Awakening dormant haematopoietic stem cells. Nat Rev Immunol 10(3):201–209CrossRefPubMed
15.
Simonsson B, Gedde-Dahl T, Markevärn B, Remes K, Stentoft J, Nordic CML Study Group et al (2011) Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 118(12):3228–3235CrossRefPubMed
16.
Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K (2011) Interferon alpha for treatment of chronic myeloid leukemia. Curr Drug Targets 12(3):420–428CrossRefPubMed
17.
Talpaz M, Mercer J, Hehlmann R (2015) The interferon-alpha revival in CML. Ann Hematol 94(Suppl 2):S195–S207CrossRefPubMed
18.
Cayssials E, Guilhot F (2016) Beyond tyrosine kinase inhibitors: combinations and other agents. Best Pract Res Clin Haematol 29(3):271–283CrossRefPubMed
19.
Kiladjian JJ, Cassinat B, Turlure P et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037–2040CrossRefPubMed
20.
Kiladjian JJ, Chomienne C, Fenaux P (2008) Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22(11):1990–1998CrossRefPubMed
21.
Kiladjian JJ, Mesa RA, Hoffman R (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18):4706–4715CrossRefPubMed
22.
Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ (2011) Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 12(3):392–419CrossRefPubMed
23.
Hasselbalch HC (2011) A new era of interferon-alpha2 in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 4(6):637–655CrossRefPubMed
24.
Silver RT, Kiladjian JJ, Hasselbalch HC (2013) Interferon in the treatment of essential thrombocythemia, polycythemia vera and myelofibrosis. Expert Rev. Hematology 6(1):49–58CrossRef
25.
Hasselbalch HC, Silver RT (2015) Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial? Expert Rev Hematol 8(4):439–445CrossRefPubMed
26.
Kiladjian JJ, Giraudier S, Cassinat B (2016) Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 30(4):776–781CrossRefPubMed
27.
Samuelsson J, Hasselbalch H, Bruserud O et al (2006) A phase II trial of pegylated interferon alpha- 2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106:2397–2405CrossRefPubMed
28.
Steimle C, Lehmann U, Temerinac S et al (2007) Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann Hematol 86(4):239–244CrossRefPubMed
29.
Kiladjian JJ, Cassinat B, Chevret S et al (2008) Pegylated interferon-alfa-2a induces complete haematological and molecular responses with low toxicity in polycythemia vera. Blood 112(8):3065–3072CrossRefPubMed
30.
Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC (2008) Complete molecular remission of polycythemia vera during long-term treatment with pegylated interferon alpha-2b. Ann Hematol 87:847–850CrossRefPubMed
31.
Larsen TS, Møller MB, de Stricker K et al (2009) Minimal residual disease and normalization of the bone marrow after long-term treatment with alphainterferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission. Hematology 14(6):331–334CrossRefPubMed
32.
Quintás-Cardama A, Kantarjian H, Manshouri T et al (2009) Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 27(32):5418–5424CrossRefPubMedPubMedCentral
33.
Larsen TS, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC (2013) Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha. Leuk Res;37(9):1041–1045
34.
Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos P, Cross NC, Silver RT (2012) Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica 97(4):538–542CrossRefPubMedPubMedCentral
35.
Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL (2014) Interferon-alpha2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res 38(10):1177–1183CrossRefPubMed
36.
Quintás-Cardama A, Abdel-Wahab O, Manshouri T et al (2013) Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood 122(6):893–901CrossRefPubMedPubMedCentral
37.
Them NC, Bagienski K, Berg T, Gisslinger B, Schalling M, Chen D, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Zagrijtschuk O, Klade C, Greil R, Gisslinger H, Kralovics R (2015) Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol 90(4):288–294CrossRefPubMedPubMedCentral
38.
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, Wolf D, Kralovics R, Gisslinger B, Strecker K, Egle A, Melchardt T, Burgstaller S, Willenbacher E, Schalling M, Them NC, Kadlecova P, Klade C, Greil R (2015) Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126(15):1762–1769CrossRefPubMedPubMedCentral
39.
Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ (2015) Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood 126(24):2585–2591CrossRefPubMed
40.
King KY, Matatall KA, Shen CC, Goodell MA, Swierczek SI, Prchal JT (2015) Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells. Exp Hematol 43(10):912–918CrossRefPubMedPubMedCentral
41.
Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, Hasselbalch HC (2015) Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera. Leuk Lymphoma; 1–7
42.
Kovacsovics-Bankowski M, Kelley TW, Efimova O, Kim SJ, Wilson A, Swierczek S, Prchal J (2016) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2V617F allelic burden. Exp Hematol Oncol 5:28 eCollection 2015CrossRefPubMedPubMedCentral
43.
Kjær L, Cordua S, Holmström MO, Thomassen M, Kruse TA, Pallisgaard N, Larsen TS, de Stricker K, Skov V, Hasselbalch HC. Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment. PLoS One 2016;11(10):e0165336. doi: https://​doi.​org/​10.​1371/​journal.​pone.​0165336. eCollection 2016
44.
O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C (2016) Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol 95(5):733–738CrossRefPubMed
45.
Gowin K, Jain T, Kosiorek H, Tibes R, Camoriano J, Palmer J, Mesa R (2017) Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial. Leuk Res 54:73–77CrossRefPubMed
46.
47.
48.
49.
Tashi T, Swierczek S, Kim SJ, Salama ME, Song J, Heikal N, King KY, Hickman K, Litton S, Prchal JT (2018, 2018) Pegylated interferon alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia. https://​doi.​org/​10.​1038/​s41375-018-0080-6 [Epub ahead of print]
50.
Lindgren M, Samuelsson J, Nilsson L, Knutsen H, Ghanima W, Westin J, Johansson PL, Andréasson B (2018) Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms. Eur J Haematol 100(5):419–425CrossRefPubMed
51.
Bjørn ME, Hasselbalch HC (2017) Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib. Expert Rev Hematol 10(5):393–404CrossRefPubMed
52.
Holmström MO, Hasselbalch HC (2018) Cancer immune therapy for myeloid malignancies – present and future. Sem Immunopathol Submitted
53.
Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H (1985) Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytosis. Acta Med Austriaca 12(5):123–127PubMed
54.
Ludwig H, Linkesch W, Gisslinger H et al (1987) Interferon alfa corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol Immunother 25:266–273CrossRefPubMed
55.
Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22(Suppl 1):135–142CrossRefPubMed
56.
Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79(3):103–109CrossRefPubMed
57.
58.
Gilbert HS (1998) Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer 83:1205–1213CrossRefPubMed
59.
Silver RT (2006) Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha. Cancer 107:451–458CrossRefPubMed
60.
Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM (2011) Increase in circulating CD4(+) CD25(+) Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neo- plasms during treatment with IFN-alpha. Blood 118(8):2170–2173CrossRefPubMed
61.
Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Svane IM, Jensen MK (2015) Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α. Eur J Haematol 94(3):227–234CrossRefPubMed
62.
Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, Svane IM (2016) Interferon-alpha induces marked alterations in circulating regulatory T cells, NK cell subsets and dendritic cells in patients with JAK2 -positive essential thrombocythemia and polycythemia vera. Eur J Haematol 97(1):83–92CrossRefPubMed
63.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer genome project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054–1061CrossRefPubMed
64.
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature;434(7037):1144–1148
65.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloprolif- erative disorders. N Engl J Med 352(17):1779–1790CrossRefPubMed
66.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7(4):387–397CrossRefPubMed
67.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390CrossRefPubMed
68.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405CrossRefPubMedPubMedCentral
69.
Cazzola M, Kralovics R (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123(24):3714–3719CrossRefPubMed
70.
Billiau A (2006) Interferon: the pathways of discovery 1. Molecular and cellular aspects. Cytokine Growth Factor Rev 17:381–409CrossRefPubMed
71.
Dukes PP, Izadi P, Ortega JA, Shora NA, Gomperts E (1980) Inhibitory effects of interferon on mouse megakaryocytic progenitor cells in culture. Exp Hematol 8:1048PubMed
72.
Lotzova E, Savary CA, Gutterman JU, Hersch EM (1982) Modulation of natural killer cell- mediated cytotoxicity by partially purified and cloned interferon-alpha. Cancer Res 42:2480–2488PubMed
73.
Neumann HA, Fauser AA (1982) Effect of interferon on pluripotent hematopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 10:587–590PubMed
74.
Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotent (CFU-GEMM), erytrhoid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131:1300–1305PubMed
75.
Ganser A, Carlo-Stella C, Greher J, Volkers B, Holzer D (1987) Effect of interferons alpha and gamma on human bone marrow-derived megakaryocytic progenitor cells. Blood 70:1173–1179PubMed
76.
Nissen MH, Larsen JK, Plesner T, Olesen BK, Ernst P (1987) Alpha interferon induces enhanced expression of HLA-ABC antigens and beta2-microglobulin in vivo and in vitro in various subsets of human lymphoid cells. Clin Exp Immunol 69:632–638PubMedPubMedCentral
77.
Carlo Stella C, Cazolla M, Ganser A et al (1987) Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood 70:1014–1019PubMed
78.
Carlo Stella C, Cazzola M (1988) Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Hematologica 1988(73):225
79.
Gugliotta L, Bagnara GP, Catani L, Gaggiol L, Guarni A, Zauli G (1989) In vivo and in vitro inhibitory effect of interferon on megakaryocyte colony growth in essential thrombocythemia. Br J Hematol 71:177–181CrossRef
80.
Chott A, Gisslinger H, Thiele J et al (1990) Interferon-alpha-induced morphological changes of megakaryocytes: a histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br J Hematol 74:10–16CrossRef
81.
Muller CA, Walz J, Zinser R, Buhring HJ, Steinke B, Schmidt H (1991) In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-alfa treatment. Ann Hematol 63:259–263CrossRefPubMed
82.
Wadenvik H, Kutti J, Ridelli B et al (1991) The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 77:2103–2108PubMed
83.
Franco V, Florena AM, Aragona F, Campesi G (1993) Morphometric study of the bone marrow in polycythemia vera following interferon therapy. Pathol Res Pract 189:52–57CrossRefPubMed
84.
Castello G, Lerza R, Cerruti A et al (1994) The in vitro effect of recombinant interferon-alpha-2a on circulating hematopoietic progenitors in polycythemia vera. Br J Hematol 87:621–623CrossRef
85.
Peschel C, Aulitzky WE, Huber C (1996) Influence of interferon –alpha on cytokine expression by bone marrow microenvironment – impact on treatment of myeloproliferative disorders. Leukemia Lymphoma 22(Suppl 1):129–134CrossRefPubMed
86.
Grander D, Sangfelt O, Erickson S (1997) How does interferon exert its cell growth inhibitory effect? Eur J Hematol 59:129–135CrossRef
87.
Wang O, Miyakawa Y, Fox N et al (2000) Interferon-alfa directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 96:2093–2097PubMed
88.
Brassard DL, Grace MJ, Bordens RW (2002) Interferon-alpha as an immunotherapeutic protein. J Leucocyte Biol 71:565–581
89.
Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89:884–893CrossRefPubMed
90.
Bracci L, Proietti E, Belardelli F (2007) IFN-alpha and novel strategies of combination therapy for cancer. Ann N Y Acad Sci 1112:256–268CrossRefPubMed
91.
Xu D, Erickson S, Szeps M, Gruber A, Sangfelt O, Einhorn S, Pisa P, Grandér D (2000) Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 96(13):4313–4318PubMed
92.
Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, Spitzer G, Odenike O, McDevitt MA et al (2015) Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med 373(10):920–928CrossRefPubMed
93.
Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM et al (2015) A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med 373(10):908–919CrossRefPubMed
94.
Armanios M, Greider CW (2015) Treating myeloproliferation — on target or off? N. Engl. J Med 373(10):965–966CrossRefPubMed
95.
Bjørn ME, Nielsen CH, Hasselbalch HC (2015) Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis. N Engl J Med 373(26):2579–2580CrossRefPubMed
96.
Frazier KS (2015) Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist’s perspective. Toxicol Pathol 43(1):78–89CrossRefPubMed
97.
Swierczek S, Kelley TW, King KY, Ching-Chieh S, Hickman K, Kim SJ, et al (2012) Salutary effect of pegylated interferon in PV and ET as evaluated by quantitation of Pre-JAK2V617F and JAK2V617F-bearing stem cells and granulocytes and correlation with circulating regulatory T cells and HSC cell cycle status. Blood 2012 (ASH Annu Meet Abstr 2012 120 Abstr 807)
98.
Holmström MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH (2016) The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia 30(12):2413–2416CrossRefPubMed
99.
Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C et al (2017) The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia 31(2):495–498CrossRefPubMed
100.
101.
Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L (2018) The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 32(2):429–437CrossRefPubMed
102.
103.
Skov V, Riley CH, Thomassen M, Larsen TS, Jensen MK, Bjerrum OW et al (2013) Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis. Leuk Lymphoma 54(10):2269–2273CrossRefPubMed
104.
105.
Frederiksen H, Farkas DK, Christiansen CF et al (2011) Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 118:6515–6520CrossRefPubMed
106.
Frederiksen H, Farkas DK, Christiansen CF et al (2015) Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. Lancet. Haematol 2:e289–e296
107.
Pettersson H, Knutsen H, Holmberg E, Andréasson B (2015) Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis. Eur J Haematol 94(2):152–156CrossRefPubMed
108.
Hasselbalch HC (2015) Perspectives on the increased risk of second cancer in patients with essential thrombocythemia, polycythemia vera and myelofibrosis. Eur J Haematol 94:96–98CrossRefPubMed
109.
Skov V, Riley CH, Thomassen M, Kjær L, Stauffer Larsen T, Bjerrum OW, Kruse TA, Hasselbalch HC (2017) The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms. Leuk Lymphoma 58(8):1914–1921CrossRefPubMed
110.
111.
Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I (2013) A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia 27(11):2187–2195CrossRefPubMed
112.
Hasselbalch HC, Thomassen M, Riley CH, Kjær L, Larsen TS, Jensen MK, Bjerrum OW, Kruse TA, Skov V (2014) Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One 9(11):e112786. https://​doi.​org/​10.​1371/​journal.​pone.​0112786 eCollection 2014CrossRefPubMedPubMedCentral
113.
114.
Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, Passegué E (2014) Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 211(2):245–262CrossRefPubMedPubMedCentral
115.
Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T et al (2013) Depletion of Jak2V617F myeloproliferative neoplasm- propagating stem cells by interferon-a in a murine model of polycythemia vera. Blood 121(18):3692–36702CrossRefPubMedPubMedCentral
116.
117.
Hasselbalch HC (2017) Molecular profiling as a novel tool to predict response to interferon-α2 in MPNs: the proof of concept in early myelofibrosis. Cancer 123(14):2600–2603CrossRefPubMed
118.
Stein BL, Tiu RV (2013) Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. J Interf Cytokine Res 33(4):145–153CrossRef
119.
120.
121.
Marchioli R, Finazzi G, Landolfi R et al (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232CrossRefPubMed
122.
Sørensen AL, Hasselbalch HC (2016) Antecedent cardiovascular disease and autoimmunity in Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 41:27–35CrossRefPubMed
123.
Enblom-Larsson A, Girodon F, Bak M, Hersby D, Jooste V, Hasselbalch HC, Johansson P, Andreasson B (2017) A retrospective analysis of the impact of treatments and blood counts on survival and the risk of vascular events during the course of polycythaemia vera. Br J Haematol. https://​doi.​org/​10.​1111/​bjh.​14625 [Epub ahead of print]
124.
Hasselbalch HC (2013) Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res 37(2):214–220CrossRefPubMed
125.
Hasselbalch HC (2012) Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 119:3219–3225CrossRefPubMed
126.
Hasselbalch HC (2013) The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 24(2):133–145CrossRefPubMed
127.
128.
Koschmieder S, Mughal TI, Hasselbalch HC et al (2016) Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30(5):1018–1024CrossRefPubMed
129.
Geyer HL, Dueck AC, Scherber RM, Mesa R (2015) Impact of inflammation on myeloproliferative neoplasm symptom burden. Mediat Inflamm 2015:284706
130.
Bak M, Sørensen TL, Flachs EM, Zwisler AD, Juel K, Frederiksen H, Hasselbalch HC (2017) Age-related macular degeneration in patients with chronic myeloproliferative neoplasms. JAMA Ophthalmol 135(8):835–843CrossRefPubMedPubMedCentral
131.
Christensen AS, Møller JB, Hasselbalch HC (2014) Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res 38(4):490–495CrossRefPubMed
132.
Farmer S, Horváth-Puhó E, Vestergaard H, Hermann AP, Frederiksen H (2013) Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol 163(5):603–610CrossRefPubMed
133.
Farmer S, Ocias LF, Vestergaard H, Broesby-Olsen S, Hermann AP, Frederiksen H (2015) Bone morbidity in chronic myeloproliferative neoplasms. Expert Rev Hematol 8(4):447–456CrossRefPubMed
134.
Farmer S, Shanbhogue VV, Hansen S, Stahlberg CI, Vestergaard H, Hermann AP, Frederiksen H (2017) Bone mineral density and microarchitecture in patients with essential thrombocythemia and polycythemia vera. Osteoporos Int 28(2):677–668CrossRefPubMed
135.
136.
Lussana F, Carobbio A, Salmoiraghi S, Guglielmelli P, Vannucchi AM, Bottazzi B et al (2017) Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol 22(10(1)):1054
137.
138.
139.
Pikarsky E, Porat RM, Stein I et al (2004) NF-kappaB functions as a tumour promoter in inflammation associated cancer. Nature 431(7007):461–466CrossRefPubMed
140.
Pittet MJ, Swirski FK (2011) Monocytes link atherosclerosis and cancer. Eur J Immunol 41(9):2519–2522CrossRefPubMed
141.
Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE et al (2018) Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Leuk Res 67:67–74CrossRefPubMedPubMedCentral
142.
Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC (2011) Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur J Haematol 87(1):54–60CrossRefPubMed
143.
Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC (2012) Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance. Leuk Res;36(11):1387–1392
144.
Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS (2012) Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis. Exp Hematol 40(9):771–780CrossRefPubMed
145.
Belikov AV, Schraven B, Simeoni L (2015) T cells and reactive oxygen species. J Biomed Sci 22:1–11CrossRef
146.
Chen X, Song M, Zhang B, Zhang Y (2016) Reactive oxygen species regulate T cell immune response in the tumor microenvironment. Oxid Med Cell Longev; 11–16
147.
148.
149.
Kameda T, Shide K, Yamaja T et al (2015) Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125(2):304–315CrossRefPubMed
150.
Moran-Crusio K, Reavie L, Shih A et al (2011) Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20:11–24CrossRefPubMedPubMedCentral
151.
Takizawa H, Boettcher S, Manz MG (2012) Demand –adapted regulation of early hematopoiesis in infection and inflammation. Blood 119(13):2991–3002CrossRefPubMed
152.
Lundberg P, Karow A, Nienhold R et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123(14):2220–2228CrossRefPubMed
153.
154.
Barraco D, Cerquozzi S, Gangat N et al (2017) Monocytosis in polycythemia vera: clinical and molecular correlates. Am J Hematol 92(7):640–645CrossRefPubMed
155.
Boyd MT, Maclean N, Oscier DG (1989) Detection of retrovirus in patients with myeloproliferative disease. Lancet 1(8642):814–817CrossRefPubMed
156.
Morgan D, Brodsky I (2004) Human endogenous retrovirus (HERV-K) particles in megakaryocytes cultured from essential thrombocythemia peripheral blood stem cells. Exp Hematol 32(6):520–525CrossRefPubMed
157.
Dvorak HF (1986) Tumors: wounds that do not heal, Similarities between tumor stroma generation and wound healing. N Engl J Med 315(26):1650–1659CrossRefPubMed
158.
Kissova J, Ovesna P, Penka M, Bulikova A, Kiss I (2014) Second malignancies in Philadelphia-negative myeloproliferative neoplasms- single-center experience. Anticancer Res 34:2489–2496PubMed
159.
Hansen IO, Sørensen AL, Hasselbalch HC (2017) Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. Eur J Haematol 98(1):75–84CrossRefPubMed
160.
Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118(7):1723–1735CrossRefPubMed
161.
Challen GA, Sun D, Jeong M et al (2012) Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44(1):23–31CrossRef
162.
Quivoron C, Couronn’e L, Della Valle V et al (2011) TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 20(1):25–38CrossRefPubMed
163.
Li Z, Cai X, Cai CL et al (2011) Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118(17):4509–4518CrossRefPubMedPubMedCentral
164.
Figueroa ME, Abdel-Wahab O, Lu C et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553–567CrossRefPubMedPubMedCentral
165.
Kiladjian JJ, Masse A, Cassinat B et al (2010) French intergroup of myeloproliferative neoplasms (FIM). Clinical analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 24(8):1519–1523CrossRefPubMed
166.
Ko M, Bandukwala HS, An J et al (2011) Ten-eleventranslocation2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 108(35):14566–14571CrossRefPubMedPubMedCentral
167.
Sasaki M, Knobbe CB, Munger JC et al (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488(7413):656–659CrossRefPubMedPubMedCentral
168.
Silver RT, Barela A, Lascu E et al (2017) The effect of initial molecular profile on response to recombinant interferon alfa (rIFNa) treatment in early myelofibrosis. Cancer 123:2680–2687CrossRefPubMed
169.
Silver RT, Vandris K (2009) Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early myelofibrosis. Leukemia 23:1366–1369CrossRefPubMed
170.
Silver RT, Vandris K, Goldman JJ (2011) Recombinant interferon alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117:6669–6672CrossRefPubMed
171.
Pizzi M, Silver RT, Barel A, Orazi A Recombinant interferon-a in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 28:1315–1323
172.
Buxhofer-Ausch V, Gisslinger H, Berg T et al (2009) Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur J Haematol 82:161–163CrossRefPubMed
173.
Wei-Chun HF, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY (2012) Inflammatory signaling compromises cell responses to interferon. Oncogene 31(2):161–172CrossRef
174.
Messina JL, Yu H, Riker AI, Munster PN, Jove RI, Daud AI (2008) Activated STAT-3 in melanoma. Cancer Control 15:196–201CrossRefPubMed
175.
Bona DD, Cippitelli M, Fionda C, Camma C, Licata A, Santoni A, Craxi A (2006) Oxidative stress inhibits IFN-alpha2-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 45:271–279CrossRefPubMed
176.
177.
Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC (2014) Combination therapy with interferon and JAK1-2 inhibitor is feasible: proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera. Leuk Res Rep 3(2):73–75PubMedPubMedCentral
178.
Mikkelsen SU, Kjaer L, Bjørn ME, Knudsen TA, Sørensen AL, Andersen CBL et al (2018) Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Med 2018 Jun 22. doi: https://​doi.​org/​10.​1002/​cam4.​1619. [Epub ahead of print]
179.
Hasselbalch HC, Riley CH (2006) Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res 30(10):1217–1225CrossRefPubMed
180.
Sørensen AL, Kallenbach K, Hasselbalch HC (2016) A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leuk Res Rep 6:20–33PubMedPubMedCentral
181.
Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802CrossRefPubMed
182.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401CrossRefPubMed
183.
Hasselbalch HC (2014) The platelet-cancer loop in myeloproliferative cancer. Is thrombocythemia an enhancer of cancer invasiveness and metastasis in essential thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 38(10):1230–1236CrossRefPubMed
184.
Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160(1):70–79CrossRefPubMed
185.
186.
Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL (2011). Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia;25(5):739–748
187.
Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Groupe Francophone des Myelodysplasies (GFM) et al (2010) treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116(19):3735–3742CrossRefPubMed
188.
Assi R, Kantarjian HM, Garcia-Manero G, Cortes JE, Pemmaraju N, Wang X et al (2018) A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. Am J Hematol 93(2):277–285CrossRefPubMed
189.
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162(5):974–986CrossRefPubMedPubMedCentral
190.
Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162(5):961–973CrossRefPubMedPubMedCentral
191.
Aaboe-Jørgensen M, Holmstrøm MO, Martinenaite E, Riley CH, Hasselbalch HC, Andersen MH (2018) Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation. OncoImmunology doi: 10.1080/2162402X.2018.1468957
Metadata
Title
Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Authors
Hans Carl Hasselbalch
Morten Orebo Holmström
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 1/2019
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-018-0700-2

Other articles of this Issue 1/2019

Seminars in Immunopathology 1/2019 Go to the issue

Review

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

Introduction

Anti-cancer immunotherapy: breakthroughs and future strategies

Review

Acquired resistance to cancer immunotherapy

Review

Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer

Review

Therapeutic cancer vaccine: building the future from lessons of the past

Review

Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits